Payment overview · 2025
General Payments
$328.05
14 reported records · 9 companies
Healthcare provider profile · identity verified
Mavis D Fujii, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HOUSTON, TX · NPI 1013099399
Verified facts
What the public records show
CMS Open Payments records show Mavis D Fujii, M.D. received $328.05 in general payments during 2025 across 14 reported records.
UCB, Inc. accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gammaked.
Kedrion Biopharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAKED as an associated drug or biological on 761 records involving 541 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gammaked by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $93.05 | 28.4% | 3 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $65.18 | 19.9% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.99 | 10.1% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.33 | 8.3% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $24.48 | 7.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.42 | 7.4% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $21.42 | 6.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.72 | 6.3% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $18.46 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $328.05 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $93.05 | 3 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $65.18 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GAMMAKED gammaked |
2025 | Gammaked | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Kedrion Biopharma, Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAKED open payments reported associated product |
CMS Open Payments — General Payments 761 supporting records · 541 recipient NPIs · example record 1206766586 |
Gammaked · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Sodium Chloride | 0.9 % Sodium Chloride | 135 | 14 |
| Diazepam | Diazepam | 78 | 16 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 78 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 68 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 62 | 12 |
| Valproate Sodium | Valproic Acid (As Sodium Salt) | 62 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 52 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 46 | suppressed |
| Gabapentin | Gabapentin | 40 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 40 | suppressed |
| Prednisone | Prednisone | 35 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 26 | suppressed |
| Famotidine | Famotidine/Pf | 24 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Bivigam | Immun Glob G(Igg)/Gly/Iga Ov50 | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 12 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 12 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $328.05 · 14 records | UCB, Inc. | ACTHAR, Albuked, GAMMAKED, GOMEKLI, HYQVIA, KEDRAB, KOATE, Ocrevus Zunovo, PURIFIED CORTROPHIN GEL, RhoGAM Ultra-Filtered PLUS, Rystiggo, Symbravo, ULTOMIRIS | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gammaked play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Kedrion Biopharma, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error